Skip to main content

Table 4 Relationships between the prognostic (+/- relapses) and the mRNA levels of the 47 selected genes in 100 ERα-positive breast tumors

From: Identification of a three-gene expression signature of poor-prognosis breast carcinoma

GENES Tumors without relapses (n = 63) Tumors with relapses (n = 37) P a ROC-AUCb
BRCA2 4.6 (1.0–12.4) c 7.1 (1.9–18.8) 0.0011 0.696 (0.59–0.80) d
DNMT3B 3.0 (1.0–13.6) 4.6 (1.2–17.4) 0.0015 0.690 (0.58–0.80)
CCNE1 6.2 (1.0–36.9) 8.9 (3.1–82.5) 0.0038 0.674 (0.57–0.78)
HMMR/RHAMM 18.9 (1.0–163.5) 30.1 (3.8–186.5) 0.0068 0.663 (0.55–0.77)
MKI67 9.1 (1.0–49.8) 14.4 (1.7–54.9) 0.016 0.645 (0.53–0.75)
TERT 18.7 (1.0–121.9) 22.1 (1.8–135.8) 0.049 0.618 (0.50–0.73)
TOP2A 40.9 (1.0–306) 55.6 (6.1–317) NS 0.605 (0.49–0.72)
PLAU/UPA 4.6 (1.0–36.4) 5.8 (1.4–34.0) NS 0.588 (0.47–0.70)
CGB 4.2 (1.0–31.2) 6.4 (1.4–32.8) NS 0.579 (0.46–0.70)
ERBB2 14.0 (1.0–175) 16.3 (4.2–179.8) NS 0.573 (0.46–0.69)
BRCA1 11.9 (1.0–44.5) 14.3 (1.8–62.5) NS 0.569 (0.45–0.69)
CXCR4 6.5 (1.0–40.5) 7.5 (1.5–71.5) NS 0.569 (0.45–0.68)
PTTG1/Securin 1.9 (1.0–26.9) 1.9 (1.2–33.1) NS 0.566 (0.45–0.68)
SRC 2.6 (1.0–4.3) 2.9 (1.4–10.2) NS 0.561 (0.45–0.67)
p16/CDKN2A 3.4 (1.0–107.4) 4.4 (1.1–136.7) NS 0.560 (0.44–0.68)
AREG 89.3 (1.0–5667) 110.1 (3.1–3301) NS 0.555 (0.44–0.67)
SERPINE1/PAI1 3.8 (1.0–21.4) 4.5 (1.3–21.8) NS 0.554 (0.44–0.67)
ERBB3 2.6 (1.0–10.7) 3.3 (1.2–13.4) NS 0.552 (0.44–0.67)
SERPINB5/Maspin 12.6 (1.0–321) 16.4 (1.0–718) NS 0.551 (0.43–0.67)
CDH1 11.3 (1.0–32.6) 13.9 (1.5–33.3) NS 0.549 (0.43–0.67)
p15/CDKN2B 3.5 (1.0–16.2) 4.2 (1.0–34.9) NS 0.548 (0.43–0.67)
SPP1/Osteopontin 43.3 (1.0–1403) 56.8 (2.1–941) NS 0.548 (0.42–0.68)
ETV4/PEA3/E1AF 5.1 (1.0–49.3) 6.9 (1.8–62.0) NS 0.545 (0.43–0.66)
CP/Ceruloplasmin 33.5 (1.0–9815) 81.5 (1.0–33943) NS 0.545 (0.42–0.67)
SERPINB2/PAI2 13.0 (1.0–498) 15.3 (1.0–1652) NS 0.535 (0.42–0.65)
TIAM1 13.6 (1.0–55.9) 13.3 (3.9–83.2) NS 0.526 (0.41–0.64)
RB1 4.2 (1.0–7.4) 4.3 (1.5–7.7) NS 0.520 (0.40–0.64)
AR 54.2 (1.0–219) 64.8 (1.0–211) NS 0.518 (0.40–0.64)
HAS2 6.5 (1.0–40.8) 6.4 (1.4–31.9) NS 0.516 (0.40–0.63)
TFF1/pS2 1772 (1.0–138 545) 1783 (3–55 878) NS 0.509 (0.39–0.62)
ESR2/ERβ 28.2 (1.0–368) 25.3 (1.4–219) NS 0.500 (0.38–0.62)
ERBB4 141 (1.0–1489) 143 (2.1–1062) NS 0.483 (0.37–0.60)
KRT19 14.4 (1.6–99.1) 10.8 (1.0–57.1) NS 0.482 (0.36–0.60)
ESR1/ERα 25.5 (1.0–508) 21.7 (1.2–498) NS 0.479 (0.36–0.60)
CXCL12 12.1 (1.3–36.1) 9.6 (1.0–30.5) NS 0.464 (0.35–0.58)
MYC 8.1 (1.0–35.5) 7.5 (1.0–51.2) NS 0.464 (0.35–0.58)
EGFR/ERBB1 8.3 (1.2–108) 6.2 (1.0–66.8) NS 0.462 (0.34–0.58)
ARHC/RhoC 6.9 (1.0–192) 6.3 (1.0–17.2) NS 0.458 (0.34–0.58)
p14/ARF 4.9 (1.4–68.1) 4.4 (1.0–61.2) NS 0.457 (0.34–0.57)
XLKD1/LYVE-1 4.5 (1.4–10.9) 3.7 (1.0–10.7) NS 0.448 (0.33–0.57)
CD44 3.1 (1.2–9.6) 2.7 (1.0–8.4) NS 0.440 (0.32–0.56)
CGA 17.6 (1.0–16 552) 6.4 (1.0–5 836) NS 0.425 (0.31–0.54)
CAV1 7.4 (1.1–30.7) 5.6 (1.0–26.6) NS 0.422 (0.31–0.54)
BCL2 4.9 (1.2–13.3) 3.2 (1.0–11.8) NS 0.415 (0.30–0.53)
PGR/PR 277 (1.0–8 034) 97 (1.0–4 551) NS 0.412 (0.29–0.53)
PTGS2/COX2 4.6 (1.0–154) 3.0 (1.0–14.8) NS 0.397 (0.28–0.51)
CCND1 6.3 (1.2–45.3) 4.0 (1.0–21.3) 0.042 0.378 (0.26–0.50)
  1. a:P value, Mann-Whitney U test ; NS, not significant
  2. b:ROC (Receiver Operating Characteristics) – AUC (Area Under Curve) analysis
  3. c:Median (range) of gene mRNA levels
  4. d:AUC value (95% confidence interval)